GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Forward PE Ratio

Spago Nanomedical AB (OSTO:SPAGO) Forward PE Ratio : 0.00 (As of Jun. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Forward PE Ratio?

Spago Nanomedical AB's Forward PE Ratio for today is 0.00.

Spago Nanomedical AB's PE Ratio without NRI for today is 0.00.

Spago Nanomedical AB's PE Ratio for today is 0.00.


Spago Nanomedical AB Forward PE Ratio Historical Data

The historical data trend for Spago Nanomedical AB's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Forward PE Ratio Chart

Spago Nanomedical AB Annual Data
Trend 2021-12 2022-09
Forward PE Ratio
9.41 4.68

Spago Nanomedical AB Quarterly Data
2021-09 2021-12
Forward PE Ratio 13.97 9.41

Competitive Comparison of Spago Nanomedical AB's Forward PE Ratio

For the Biotechnology subindustry, Spago Nanomedical AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Forward PE Ratio falls into.



Spago Nanomedical AB Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Spago Nanomedical AB  (OSTO:SPAGO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Spago Nanomedical AB Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB (OSTO:SPAGO) Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines